TickerGuard
Buy Day today: Poor (44) Weak market breadth · today: Core PCE (August) ≈
CAI

Caris Life Sciences, Inc.

Healthcare · Biotechnology · —

31.70$ +0.6% vs. previous close Closing price · As of: Sep 23, 2026

Statements

Cash Flow

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Cash Flow CAI
Line item 2013 2014 2015 2016 2017 2018 2019 2020 2022 2023 2024 2025
58.5% 61.4% 59.0% 43.9% 44.5% 41.6% 61.0% 94.2% -110.5% -90.2% -59.5% 10.2%
32.2% 34.6% 45.8% 36.2% 32.5% 28.6% 27.4% 37.6% 18.7% 16.0% 11.9% 2.8%
0.7% 0.8% 0.8% 0.6% 0.6% 0.7% 0.7% 0.6% 8.9% 5.0% 4.5% 8.6%
-6.7% -34.5% 12.3% 15.3% -26.0% -19.9% 100.2% -107.9% -8.6% -2.3% -7.1% -4.1%
147.0% 135.0% 156.0% 85.4% 144.1% 188.1% 76.6% 74.6% 16.3% 7.3% 2.0% 2.0%
-125.6% -99.0% -122.3% -61.7% -118.2% -153.5% -65.3% -11.6% -109.5% 70.2% 12.8% -2.0%
– – – – – 0.8% 2.1% 6.0% – – – –
– -13.8% -5.2% -3.1% – -9.5% -8.2% -2.7% – 0.0% 0.0% 0.0%
– – – – – – – – -0.4% 3.5% 48.5% 3.4%
81.0% 41.8% 62.7% 15.8% 70.5% 118.6% -26.0% -85.0% 4.0% 3.3% 48.6% 81.9%
13.2% 3.6% -0.5% -2.2% -3.1% 6.7% -0.7% -2.3% -216.0% -16.7% 1.9% 90.1%
-88.5% -73.7% -96.9% -41.4% -99.6% -146.5% -15.6% 19.6% -126.9% -97.5% -61.5% 8.2%

Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?